Sarepta slides as Wall Street digests gene therapy trial push out, adverse event

Shares of Sarepta Therapeutics (SRPT), which had been lower following the company’s quarterly report, fell further on Thursday prior to trading of the stock being halted after a serious adverse event linked to its SRP-9001 treatment was added to a Food and Drug Administration’s database that tracks such adverse events. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2948396/-Sarepta-slides-as-Wall-Street-digests-gene-therapy-trial-push-out-adverse-event)